Dispatch Bio: Toward tumor-agnostic immunotherapy

A group of powerhouse academics, brought together by the Parker Institute, are combining their discoveries to create a universal therapy for epithelial tumors.

Launched in July, their company, Dispatch Biotherapeutics Inc., aims to address multiple cancer defenses simultaneously, enabling treatment of many cancers with the same combination therapy, which pairs CAR T cells with a tumor-targeted virus...